|
Oct 15
|
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
|
|
Oct 1
|
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
|
|
Sep 30
|
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
|
Jul 25
|
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
|
|
Jun 24
|
Crypto under pressure, Good Buy or Goodbye: Market Domination
|
|
Jun 24
|
Altimmune reports positive results in weight-loss drug trial
|
|
Jun 23
|
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
|
|
Jun 22
|
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
|
|
Jun 21
|
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
|
|
Jun 20
|
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
|
|
Jun 18
|
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
|
|
Jun 5
|
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
|
May 11
|
Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)
|
|
May 9
|
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
|
|
May 7
|
Altimmune to Participate at Two Upcoming Investor Conferences
|
|
May 2
|
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
|
|
May 1
|
Altimmune to Participate at Two Upcoming Conferences
|
|
Apr 25
|
Altimmune Statement on the Passing of Dr. Stephen Harrison
|
|
Mar 27
|
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 20
|
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
|